Cargando…
Subcellular Performance of Nanoparticles in Cancer Therapy
With the advent of nanotechnology, various modes of traditional treatment strategies have been transformed extensively owing to the advantageous morphological, physiochemical, and functional attributes of nano-sized materials, which are of particular interest in diverse biomedical applications, such...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008395/ https://www.ncbi.nlm.nih.gov/pubmed/32103936 http://dx.doi.org/10.2147/IJN.S226186 |
_version_ | 1783495464792883200 |
---|---|
author | Liu, Chen-Guang Han, Ya-Hui Kankala, Ranjith Kumar Wang, Shi-Bin Chen, Ai-Zheng |
author_facet | Liu, Chen-Guang Han, Ya-Hui Kankala, Ranjith Kumar Wang, Shi-Bin Chen, Ai-Zheng |
author_sort | Liu, Chen-Guang |
collection | PubMed |
description | With the advent of nanotechnology, various modes of traditional treatment strategies have been transformed extensively owing to the advantageous morphological, physiochemical, and functional attributes of nano-sized materials, which are of particular interest in diverse biomedical applications, such as diagnostics, sensing, imaging, and drug delivery. Despite their success in delivering therapeutic agents, several traditional nanocarriers often end up with deprived selectivity and undesired therapeutic outcome, which significantly limit their clinical applicability. Further advancements in terms of improved selectivity to exhibit desired therapeutic outcome toward ablating cancer cells have been predominantly made focusing on the precise entry of nanoparticles into tumor cells via targeting ligands, and subsequent delivery of therapeutic cargo in response to specific biological or external stimuli. However, there is enough room intracellularly, where diverse small-sized nanomaterials can accumulate and significantly exert potentially specific mechanisms of antitumor effects toward activation of precise cancer cell death pathways that can be explored. In this review, we aim to summarize the intracellular pathways of nanoparticles, highlighting the principles and state of their destructive effects in the subcellular structures as well as the current limitations of conventional therapeutic approaches. Next, we give an overview of subcellular performances and the fate of internalized nanoparticles under various organelle circumstances, particularly endosome or lysosome, mitochondria, nucleus, endoplasmic reticulum, and Golgi apparatus, by comprehensively emphasizing the unique mechanisms with a series of interesting reports. Moreover, intracellular transformation of the internalized nanoparticles, prominent outcome and potential affluence of these interdependent subcellular components in cancer therapy are emphasized. Finally, we conclude with perspectives with a focus on the contemporary challenges in their clinical applicability. |
format | Online Article Text |
id | pubmed-7008395 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-70083952020-02-26 Subcellular Performance of Nanoparticles in Cancer Therapy Liu, Chen-Guang Han, Ya-Hui Kankala, Ranjith Kumar Wang, Shi-Bin Chen, Ai-Zheng Int J Nanomedicine Review With the advent of nanotechnology, various modes of traditional treatment strategies have been transformed extensively owing to the advantageous morphological, physiochemical, and functional attributes of nano-sized materials, which are of particular interest in diverse biomedical applications, such as diagnostics, sensing, imaging, and drug delivery. Despite their success in delivering therapeutic agents, several traditional nanocarriers often end up with deprived selectivity and undesired therapeutic outcome, which significantly limit their clinical applicability. Further advancements in terms of improved selectivity to exhibit desired therapeutic outcome toward ablating cancer cells have been predominantly made focusing on the precise entry of nanoparticles into tumor cells via targeting ligands, and subsequent delivery of therapeutic cargo in response to specific biological or external stimuli. However, there is enough room intracellularly, where diverse small-sized nanomaterials can accumulate and significantly exert potentially specific mechanisms of antitumor effects toward activation of precise cancer cell death pathways that can be explored. In this review, we aim to summarize the intracellular pathways of nanoparticles, highlighting the principles and state of their destructive effects in the subcellular structures as well as the current limitations of conventional therapeutic approaches. Next, we give an overview of subcellular performances and the fate of internalized nanoparticles under various organelle circumstances, particularly endosome or lysosome, mitochondria, nucleus, endoplasmic reticulum, and Golgi apparatus, by comprehensively emphasizing the unique mechanisms with a series of interesting reports. Moreover, intracellular transformation of the internalized nanoparticles, prominent outcome and potential affluence of these interdependent subcellular components in cancer therapy are emphasized. Finally, we conclude with perspectives with a focus on the contemporary challenges in their clinical applicability. Dove 2020-02-05 /pmc/articles/PMC7008395/ /pubmed/32103936 http://dx.doi.org/10.2147/IJN.S226186 Text en © 2020 Liu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Liu, Chen-Guang Han, Ya-Hui Kankala, Ranjith Kumar Wang, Shi-Bin Chen, Ai-Zheng Subcellular Performance of Nanoparticles in Cancer Therapy |
title | Subcellular Performance of Nanoparticles in Cancer Therapy |
title_full | Subcellular Performance of Nanoparticles in Cancer Therapy |
title_fullStr | Subcellular Performance of Nanoparticles in Cancer Therapy |
title_full_unstemmed | Subcellular Performance of Nanoparticles in Cancer Therapy |
title_short | Subcellular Performance of Nanoparticles in Cancer Therapy |
title_sort | subcellular performance of nanoparticles in cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008395/ https://www.ncbi.nlm.nih.gov/pubmed/32103936 http://dx.doi.org/10.2147/IJN.S226186 |
work_keys_str_mv | AT liuchenguang subcellularperformanceofnanoparticlesincancertherapy AT hanyahui subcellularperformanceofnanoparticlesincancertherapy AT kankalaranjithkumar subcellularperformanceofnanoparticlesincancertherapy AT wangshibin subcellularperformanceofnanoparticlesincancertherapy AT chenaizheng subcellularperformanceofnanoparticlesincancertherapy |